relative to treatment alternatives to opioids.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 9 Sponsors 5

Oct 19, 2022 · House

Interim Study Report: Recommended for Future Legislation (Vote 17-0)

May 24, 2022 · House

Interim Study Work Session: 06/06/2022 09:30 am LOB 201-203

Jan 11, 2022 · House

Refer for Interim Study: MA VV 01/05/2022 HJ 1

Nov 3, 2021 · House

Committee Report: Refer for Interim Study HB247 10/26/2021 (Vote 21-0; CC) HC 48 P. 12

Oct 13, 2021 · House

Executive Session: 10/26/2021 09:30 am LOB 205-207

Sep 21, 2021 · House

Subcommittee Work Session: 10/06/2021 10:00 am LOB 205-207

Feb 9, 2021 · House

Retained in Committee

Jan 20, 2021 · House

Public Hearing: 01/26/2021 11:00 am Members of the public may attend using the following link:To join the webinar: https://www.zoom.us/j/94852322897 / Executive session on pending legislation may be held throughout the day (time permitting) from the time thecommittee is initially convened.

Jan 9, 2021 · House

Introduced (in recess of) 01/06/2021 and referred to Health, Human Services and Elderly Affairs HJ 2 P. 40

PASSAGE PROBABILITY

7.9% Unlikely

Why this number

Stage base In Committee — base rate 27%, measured from NH's completed sessions
Momentum -2 40/100 from the pace of recorded action
Time since last action -22 1452 days quiet
Cosponsors +6 4 signed on
Sponsor influence -0 48/100

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.